The Pilot Project Component is designed to provide a flexible means for developing and exploring newresearch activities or directions, and unique opportunities that can evolve into independently fundedresearch projects. In addition, the Pilot Project Component provides a resource for attracting newinvestigators into drug abuse research. We propose to fund an average of three pilot projects per year withan average budget of $33K. The expected duration of these pilot projects will be 1-2 years. The CenterScientific Director will manage this Component. Pilot Project Component applications will be solicited from allOHSU- and Portland VA Medical Center-based investigators annually. Each proposal will be evaluated forscientific merit/innovation, thematic alignment and several other criteria by at least two members of theCenter's Scientific Advisory Board, the Scientific Director, and the Center Director. Recommendations forfunding will be considered for approval by the Center Executive Committee. Three pilot projects areproposed for funding in Year 1 of the Methamphetamine Abuse Research Center (MARC). Project 8A (W.Hoffman, PI) will use functional magnetic resonance imaging to study neuroanatomical associates of MAaddiction and heightened impulsivity. Project 8B (S. Mitchell, PI) will examine in mice the notion thatimpulsivity is related to MA self-administration, using a delay discounting procedure. Project 8C (J. Raber,PI) will explore the hypothesis that histamine mediates the detrimental long-term effects of neonatal MAexposure on cognition. All of these pilots are related to a Center theme at least by virtue of their examinationof MA effects. In addition, mice used in Project 8B and 8C will share genetic background with those used inScientific Components 5 and 6, and will obtain mice from the Animal Core. Pilot project 8A also relates to theCenter impulsivity, neuroadaptation and neuroanatomy themes; Pilot project 8B relates to the Centerimpulsivity theme; and Pilot project 8C relates to the Center stressor responsivity and neuroadaptationthemes. It is expected that Pilot Component projects funded in years 2-5 of the Center will contribute to thestudy of MA abuse and to one or more of the additional themes of the Center: Impulsivity, stressorresponsivity, neuroadaptation, and neuroanatomy, and to our goal of pursuing translational research inpreclinical and clinical models.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
1P50DA018165-01A1
Application #
7052365
Study Section
Special Emphasis Panel (ZDA1-RXL-E (03))
Project Start
2005-12-01
Project End
2010-11-30
Budget Start
2005-12-01
Budget End
2007-06-30
Support Year
1
Fiscal Year
2006
Total Cost
$97,651
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Holton, Dwight; White, Elizabeth; McCarty, Dennis (2018) Public Health Policy Strategies to Address the Opioid Epidemic. Clin Pharmacol Ther 103:959-962
Kohno, Milky; Loftis, Jennifer M; Huckans, Marilyn et al. (2018) The relationship between interleukin-6 and functional connectivity in methamphetamine users. Neurosci Lett 677:49-54
Shabani, Shkelzen; Schmidt, Bryan; Ghimire, Bikalpa et al. (2018) Depression-like symptoms of withdrawal in a genetic mouse model of binge methamphetamine intake. Genes Brain Behav :e12533
Eshleman, Amy J; Nagarajan, Shanthi; Wolfrum, Katherine M et al. (2018) Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology (Berl) :
McCready, Holly; Kohno, Milky; Kolessar, Michael et al. (2018) Functional MRI and delay discounting in patients infected with hepatitis C. J Neurovirol 24:738-751
Loftis, Jennifer M; Valerio, Juno; Taylor, Jonathan et al. (2018) S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder. Alcohol Clin Exp Res :
Eshleman, Amy J; Wolfrum, Katherine M; Reed, John F et al. (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27-34
Tosh, Dilip K; Ciancetta, Antonella; Mannes, Philip et al. (2018) Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. ACS Omega 3:12658-12678
McCarty, Dennis; Priest, Kelsey C; Korthuis, P Todd (2018) Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. Annu Rev Public Health 39:525-541
Eastwood, Emily C; Eshleman, Amy J; Janowsky, Aaron et al. (2018) Verification of a genetic locus for methamphetamine intake and the impact of morphine. Mamm Genome 29:260-272

Showing the most recent 10 out of 143 publications